31 completed, 5 not yet recruiting, 5 recruiting, 5 terminated. 21 Phase 3, 14 Phase 2, 10 Phase 4, 7 Phase 1.
Follow cariprazine: new trials by email Literature Review of cariprazine trials Research Report on cariprazine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Risperidone vs Cariprazine in Acute Mania Risperidone, Cariprazine - Bipolar 1 Disorder | Phase 4 | Not yet recruiting | Pakistan Institute of Medical Sciences | 50 | 2027-06-01 | 2026-06-24 |
| This Study Aims to Compare the Efficacy and Safety of Lumateperone and Cariprazine in Patients With Bipolar I Depression Using Montgomery-Åsberg Depression Rating Scale (MADRS) and Clinical Global Impression Bipolar Severity Scale (CGI-BP-S) and Recording Treatment Emergent Adverse Effects Lumateperone, Cariprazine - Bipolar 1 Depression | Phase 4 | Not yet recruiting | Watim Medical & Dental College | 140 | 2026-12-01 | 2026-10-07 |
| Longitudinal PET Imaging of Antipsychotic Binding to the Dopamine-3 Receptor in Schizophrenia Brexpiprazole, Cariprazine, [11C] PHNO - Schizoaffective Disorder, Schizophreniform Disorder | Phase 1 | Not yet recruiting | New York State Psychiatric Institute | 100 | 2026-12-01 | 2026-07-20 |
| A Study to Investigate Pharmacokinetics, Safety, and Tolerability of B2227 Extended-Release Injectable Suspension and Vraylar® in Participants With Schizophrenia 30 mg B2227, 70 mg B2227, 150 mg B2227 - Schizophrenia | Phase 2 / Phase 3 | Not yet recruiting | Bostal Drug Delivery Co., Ltd | 84 | 2026-08-01 | 2026-07-23 |
| Bioequivalence Study to Compare Cariprazine 1.5 mg Hard Capsules (1.5 mg Cariprazine Hydrochloride) Versus Reagila® 1,5 mg Hartkapseln (Hard Capsules) (Cariprazine) Cariprazine Hard Capsules, Reagila® Hartkapseln (Hard Capsules) (Cariprazine) - SCHIZOPHRENIA 1 (Disorder) | Phase 1 | Completed | Humanis Saglık Anonim Sirketi | 32 | 2026-03-05 | 2026-07-08 |
| RNA Editing as a Biomarker of Antidepressant Response in Unipolar and Bipolar Depression (EDIT-ANDRE) Vortioxetine, Cariprazine (Augmentation Phase) - Unipolar Depression, Bipolar Depression | Phase 4 | Recruiting | Mayo Clinic | 120 | 2026-02-17 | 2026-06-22 |
| Dopamine D3 Receptor Occupancy in Bipolar Depression Cariprazine - Bipolar Depression | Phase 4 | Withdrawn | New York State Psychiatric Institute | 2026-01-06 | 2026-04-14 | |
| Pharmacokinetics, Safety, Tolerability and Efficacy of a Subcutaneous Long-Acting Injection of Cariprazine (Cariprazine Depot) in Subjects Eligible for Treatment With Oral Cariprazine Cariprazine Depot, Cariprazine Depot MTD, Oral Cariprazine 3 mg/day - Schizophrenia, Bipolar I Disorder | Phase 1 / Phase 2 | Recruiting | Mapi Pharma Ltd. | 24 | 2025-08-01 | 2026-05-01 |
| Sequential Multiple Assignment Randomized Trial for Bipolar Depression Cariprazine, Aripiprazole/Escitalopram combination, Quetiapine - Bipolar I Disorder, Depression | Phase 4 | Active not recruiting | Massachusetts General Hospital | 2726 | 2024-10-01 | 2025-12-16 |
| Bioequivalence Assessment Between Two Cariprazine Hard Capsule Formulations Test Product (Vocarzine), Reference (R) Reagila ® - Bioequivalence Study in Healthy Subjects | Phase 1 | Completed | Aya Mohammed Abdel Magid Abdel Hamid | 29 | 2024-08-03 | 2025-08-17 |
| Effectiveness of Cariprazine Monotherapy for Treatment of Major Depressive Disorder Cariprazine, Treatment as usual - Depressive Disorder, Major | Phase 4 | Not yet recruiting | Sultan Qaboos University | 110 | 2024-08-01 | 2023-07-07 |
| An Exploratory Analysis of Immune and Inflammatory Response Associated With Clozapine Clozapine, Antipsychotics,Other (non-Clozapine) - Treatment-resistant Schizophrenia | Phase 4 | Terminated | Ohio State University | 5 | 2023-08-16 | 2026-02-25 |
| Lithium Versus Cariprazine in the Acute Phase Treatment of Bipolar Depression (DUAG9) Lithium, Cariprazine - Depression, Bipolar | Phase 4 | Recruiting | Aalborg University Hospital | 122 | 2022-12-13 | 2026-10-29 |
| Study to Assess Adverse Events and Change in Disease Activity of Oral Cariprazine Capsules in Adult Participants With Schizophrenia Cariprazine, Placebo - Schizophrenia | Phase 3 | Terminated | AbbVie | 34 | 2022-08-18 | 2025-10-20 |
| Cariprazine for Comorbid Cocaine and Opioid Use Disorder Cariprazine 1.5 MG, Placebo - Opioid-use Disorder, Cocaine Use Disorder | Phase 2 | Completed | Kyle Kampman | 26 | 2022-08-05 | 2026-01-23 |
| Cariprazine Versus Placebo for Social Anxiety Disorder Cariprazine, Placebo - Social Anxiety Disorder | Phase 4 | Completed | The Medical Research Network | 40 | 2022-07-18 | 2024-08-21 |
| Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD Cariprazine, Placebo - Autism Spectrum Disorder | Phase 3 | Completed | AbbVie | 161 | 2022-07-07 | 2025-04-04 |
| Adjunct Treatment With Cariprazine for Adults With Attention-deficit/Hyperactivity Disorder Cariprazine - Attention Deficit Hyperactivity Disorder | Phase 4 | Unknown | Dr. Martin A. Katzman | 15 | 2021-12-01 | 2021-12-14 |
| A Study To Assess Adverse Events and Change in Disease Activity With Oral Cariprazine When Added to Antidepressant Therapies (ADTs) Compared to Placebo in Adult Participants With Generalized Anxiety Disorder (GAD) Who Have Had an Inadequate Response to ADTs Alone Cariprazine 0.75 mg/day, Cariprazine 1.5 mg/day, Cariprazine 3.0 mg/day - Generalized Anxiety Disorder | Phase 2 | Withdrawn | AbbVie | 2021-08-18 | 2022-04-12 | |
| Assessing the Role of Cariprazine in Improving Cognition in Euthymic Bipolar Patients Cariprazine, Placebo - Bipolar I Disorder, Cognitive Impairment | Phase 3 | Terminated | Lakshmi N Yatham | 1 | 2021-07-07 | 2024-10-26 |
Showing 20 of 50. Sign in to see all of them.
Schizophrenia (16) · Depression (11) · Bipolar Disorder (9) · Depressive Disorder, Major (8) · Mania (5) · Mental Disorders (3) · Autism Spectrum Disorder (2) · Attention Deficit Disorder with Hyperactivity (1) · Autistic Disorder (1) · Cognitive Dysfunction (1) · Depressive Disorder (1) · Generalized Anxiety Disorder (1) · Impulsive Behavior (1) · Opioid-Related Disorders (1) · Phobia, Social (1)
Forest Laboratories (20) · AbbVie (9) · Gedeon Richter Plc. (2) · New York State Psychiatric Institute (2) · Aalborg University Hospital (1) · Anna Rose Childress, Ph.D. (1) · Aya Mohammed Abdel Magid Abdel Hamid (1) · Bostal Drug Delivery Co., Ltd (1) · Dr. Martin A. Katzman (1) · Humanis Saglık Anonim Sirketi (1) · Kyle Kampman (1) · Lakshmi N Yatham (1) · Mapi Pharma Ltd. (1) · Massachusetts General Hospital (1) · Mayo Clinic (1)
United States (36) · Ukraine (13) · Puerto Rico (9) · Russia (9) · India (8) · Bulgaria (7) · Romania (7) · Serbia (6) · Canada (5) · Poland (5) · Colombia (4) · Malaysia (4) · Slovakia (4) · Estonia (3) · Taiwan (3)
Willie Earley, MD (4) · Elizabeth Diaz, MD (3) · Raffaele Migliore, MA (3) · Suresh Durgam, MD (2) · Willie Earley (2) · Anna Rose Childress, PhD (1) · Aysegul Ozerdem, MD, PhD (1) · Deniz Ceylan, MD, PhD (1) · Kamal A. Badr, PhD (1) · Lakshmi N Yatham, MBBS,MRCPsyc (1) · Martin A Katzman, MD (1)
PMID 33854317, PMID 34091867, PMID 31969269, PMID 28692485, PMID 29017067, PMID 30470662, PMID 31344528, PMID 32942346, PMID 33677183, PMID 33915374, PMID 39520655, PMID 26845266, PMID 28478771, PMID 28836957, PMID 37551609, PMID 24412468, PMID 25562205, PMID 26541814, PMID 26717533, PMID 27046309, PMID 27427558, PMID 28843918, PMID 30045066, PMID 30695290, PMID 30845817, PMID 31628698, PMID 34034612, PMID 36789515, PMID 37585254, PMID 40315101, PMID 40866064, PMID 41689599
2018 (3), 2016 (2), 2017 (2), R01MH139651 (1)